Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Adenocarcinoma is the most common histological subtype of lung cancer.
• Advances in understanding non-small cell lung cancer (NSCLC) pathobiology enable targeted therapies.

Purpose of the Study:

• To define patient populations most likely to respond to targeted therapies.
• To explore the landscape of genetic mutations in lung cancer, including common and rare variants.
• To identify actionable low-frequency mutations for precision medicine.

Main Methods:

• Analysis of the lung cancer genome landscape.
• Identification of common ("mountains") and low-frequency ("hills") genetic mutations.
• Evaluation of druggable gene products affected by these mutations.

Main Results:

• The cancer genome landscape includes common driver mutations and numerous low-frequency mutations.
• Low-frequency mutations in druggable targets can be actionable.
• Targeted therapies can be selected for small patient populations based on specific mutations.

Conclusions:

• Precision medicine in lung cancer requires considering both common and rare genetic alterations.
• Identifying patients with low-frequency, actionable mutations is crucial for expanding targeted therapy options.
• Understanding the full spectrum of lung cancer mutations improves patient selection for effective treatments.